NO20062767L - Immunoglobuliner - Google Patents

Immunoglobuliner

Info

Publication number
NO20062767L
NO20062767L NO20062767A NO20062767A NO20062767L NO 20062767 L NO20062767 L NO 20062767L NO 20062767 A NO20062767 A NO 20062767A NO 20062767 A NO20062767 A NO 20062767A NO 20062767 L NO20062767 L NO 20062767L
Authority
NO
Norway
Prior art keywords
immunoglobulins
antibodies
disorders
prevention
treatment
Prior art date
Application number
NO20062767A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alexandre Eon-Duval
Robert Ian Grundy
Farhana Hussain
Ruth Mcadam
Christopher Plumpton
Rabinder Prinjha
Paul Alexander Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329711A external-priority patent/GB0329711D0/en
Priority claimed from GB0329684A external-priority patent/GB0329684D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20062767L publication Critical patent/NO20062767L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår antistoffer mot NOGO, farmasøytiske blandinger inneholdende dem og anvendelse av slike antistoffer ved behandling og/eller forebygging av nevrologiske sykdommer/lidelser.
NO20062767A 2003-12-22 2006-06-13 Immunoglobuliner NO20062767L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0329711A GB0329711D0 (en) 2003-12-22 2003-12-22 Antibodies
GB0329684A GB0329684D0 (en) 2003-12-22 2003-12-22 Method
PCT/GB2004/005325 WO2005061544A2 (en) 2003-12-22 2004-12-20 Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Publications (1)

Publication Number Publication Date
NO20062767L true NO20062767L (no) 2006-09-20

Family

ID=34712703

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062767A NO20062767L (no) 2003-12-22 2006-06-13 Immunoglobuliner

Country Status (28)

Country Link
US (4) US7988964B2 (no)
EP (3) EP1711530B1 (no)
JP (2) JP2007537145A (no)
KR (1) KR101150548B1 (no)
AR (1) AR048912A1 (no)
AT (1) ATE440866T1 (no)
AU (1) AU2004303585B2 (no)
BR (1) BRPI0417959A (no)
CA (1) CA2549956C (no)
CY (1) CY1110530T1 (no)
DE (1) DE602004022871D1 (no)
DK (1) DK1711530T3 (no)
ES (1) ES2330444T3 (no)
HK (1) HK1100144A1 (no)
HR (1) HRP20090527T1 (no)
IL (1) IL176206A (no)
IS (1) IS2739B (no)
MA (1) MA28289A1 (no)
MX (1) MXPA06007190A (no)
MY (1) MY144612A (no)
NO (1) NO20062767L (no)
NZ (1) NZ548013A (no)
PL (1) PL1711530T3 (no)
PT (1) PT1711530E (no)
RU (1) RU2362780C2 (no)
SI (1) SI1711530T1 (no)
TW (1) TWI329649B (no)
WO (2) WO2005061544A2 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
ES2330444T3 (es) * 2003-12-22 2009-12-10 Glaxo Group Limited Inmunoglobulinas neutralizantes de nogo-a para el tratamiento de enfermedades neurologicas.
NZ564567A (en) * 2005-07-05 2010-09-30 Glaxo Group Ltd Humanised antibodies specific for neurite outgrowth inhibitor-A and pharmaceutical uses thereof
ES2542501T3 (es) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
RU2442793C2 (ru) * 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2008002594A2 (en) * 2006-06-27 2008-01-03 Neuroprotection For Life Corp. Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101687032A (zh) * 2006-12-07 2010-03-31 诺瓦提斯公司 抗ephb3的拮抗剂抗体
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
US8163285B2 (en) * 2007-11-02 2012-04-24 Novartis Ag Nogo-A binding molecules and pharmaceutical use thereof
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2011521619A (ja) * 2008-04-04 2011-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍成長、血管新生および転移を妨害する癌標的に対する新規抗体
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
BR112013010544A2 (pt) * 2010-10-29 2016-08-02 Immunogen Inc moléculas de ligação ao egfr e imunoconjugados das mesmas
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
RU2014121820A (ru) 2011-11-21 2015-12-27 Иммьюноджен, Инк. Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
RU2644337C2 (ru) 2012-01-27 2018-02-08 Эббви Дойчланд Гмбх Унд Ко. Кг Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
WO2014006105A1 (en) 2012-07-05 2014-01-09 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
RS60222B1 (sr) 2015-05-04 2020-06-30 Cytomx Therapeutics Inc Anti-cd166 antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2019014586A1 (en) * 2017-07-14 2019-01-17 Cytomx Therapeutics, Inc. ANTI-CD166 ANTIBODIES AND USES THEREOF
EP3856242A4 (en) * 2018-09-25 2022-05-18 Academia Sinica ANTI-SIGLEC ANTIBODIES, PHARMACEUTICAL COMPOSITION COMPRISING IT, AND THEIR USES
JP2022553300A (ja) 2019-10-24 2022-12-22 ノヴァゴー セラピューティクス アーゲー 新規抗Ｎｏｇｏ－Ａ抗体
WO2022119932A1 (en) * 2020-12-02 2022-06-09 Agilent Technologies, Inc. Anti-human cd10 antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
ES2227769T3 (es) 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) * 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US20030113891A1 (en) * 2000-02-11 2003-06-19 Lawrence Blatt Method and reagent for the inhibition of NOGO and NOGO receptor genes
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
EP1575482A2 (en) * 2002-04-17 2005-09-21 Pharmacia & Upjohn Company LLC Compositions and method of treating alzheimer's disease
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
US20070065429A1 (en) * 2003-04-16 2007-03-22 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
ES2330444T3 (es) 2003-12-22 2009-12-10 Glaxo Group Limited Inmunoglobulinas neutralizantes de nogo-a para el tratamiento de enfermedades neurologicas.

Also Published As

Publication number Publication date
AU2004303585A1 (en) 2005-07-07
IL176206A (en) 2012-02-29
MA28289A1 (fr) 2006-11-01
CA2549956A1 (en) 2005-07-07
EP1711530B1 (en) 2009-08-26
JP4901480B2 (ja) 2012-03-21
RU2362780C2 (ru) 2009-07-27
JP2007537145A (ja) 2007-12-20
JP2008504220A (ja) 2008-02-14
ATE440866T1 (de) 2009-09-15
EP2213684A2 (en) 2010-08-04
AU2004303585B2 (en) 2010-12-23
EP1711530A2 (en) 2006-10-18
NZ548013A (en) 2009-04-30
HK1100144A1 (en) 2007-09-07
WO2005061545A2 (en) 2005-07-07
WO2005061544A2 (en) 2005-07-07
ES2330444T3 (es) 2009-12-10
DE602004022871D1 (de) 2009-10-08
US7780964B2 (en) 2010-08-24
CA2549956C (en) 2016-04-12
IS2739B (is) 2011-06-15
KR20060129290A (ko) 2006-12-15
TW200533680A (en) 2005-10-16
SI1711530T1 (sl) 2010-01-29
WO2005061544A3 (en) 2005-08-18
MXPA06007190A (es) 2006-08-23
US20110054149A1 (en) 2011-03-03
US7988964B2 (en) 2011-08-02
RU2006123481A (ru) 2008-01-27
US20140147435A1 (en) 2014-05-29
AR048912A1 (es) 2006-06-14
CY1110530T1 (el) 2015-04-29
TWI329649B (en) 2010-09-01
MY144612A (en) 2011-10-14
US20070065430A1 (en) 2007-03-22
IL176206A0 (en) 2006-10-05
KR101150548B1 (ko) 2012-07-06
EP2213684A3 (en) 2011-05-18
US20060029603A1 (en) 2006-02-09
EP1706426A2 (en) 2006-10-04
PL1711530T3 (pl) 2010-01-29
IS8506A (is) 2006-06-12
WO2005061545A3 (en) 2005-08-18
HRP20090527T1 (en) 2009-11-30
DK1711530T3 (da) 2009-12-14
PT1711530E (pt) 2009-10-22
BRPI0417959A (pt) 2007-03-27

Similar Documents

Publication Publication Date Title
NO20062767L (no) Immunoglobuliner
NO20082699L (no) Immunoglobuliner
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
MX2009006891A (es) Anticuerpos cd44.
NO20045323L (no) Antistoffer
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
WO2004080423A3 (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200709817A (en) Platform antibody compositions
NO20076663L (no) Immunoglobuliner
TW200628473A (en) Novel heterocycles
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
WO2004032864A3 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
DK1441723T3 (da) Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension
WO2004073625A3 (en) Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof
WO2004005540A3 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application